United States: Supreme Court Puts New Spin On Preemption Analysis

Last Updated: June 4 2019
Article by Paige Hester Sharpe and Neda N. Hajian

On May 20, 2019, the Supreme Court issued its opinion in Merck Sharp & Dohme Corp. v. Albrecht, No. 17-290 (May 20, 2019), a case that provided it the opportunity to clarify the standard for the impossibility preemption defense in pharmaceutical cases. While the ruling was unanimous and made clear that preemption is a question for the judge—not the jury—to decide, the Court put only a gloss on the "clear evidence" standard of Wyeth v. Levine, 555 U.S. 555 (2009), and left it to the lower courts to grapple with the application of that standard to the facts. Justice Alito's concurring opinion, however, put the statutory framework and the regulatory history of the case into greater context, suggesting that the Third Circuit should find preemption on remand and offering pharmaceutical defendants a roadmap for arguing the preemption defense in future litigation.

The Court's Decision

Merck stemmed from a large multidistrict litigation in which the plaintiffs alleged that the defendant failed to warn of the risk of severe bone breaks known as "atypical femoral fractures" associated with the osteoporosis drug Fosamax. Merck argued that FDA would have barred a warning about the fractures in the Fosamax label—as evidenced by years of back and forth with the agency and a response letter rejecting a proposed warning—and that the failure to warn claims were accordingly preempted. The district court agreed and granted Merck's motion for summary judgment. In re Fosamax (Alendronate Sodium) Prods. Liab. Litig., 951 F. Supp. 2d 695 (D.N.J. 2013). The Third Circuit reversed, finding that a jury should decide preemption as a question of fact and that "clear evidence" is a standard of proof that requires the manufacturer to show "high probability" that FDA would have rejected a label change. In re Fosamax (Alendronate Sodium) Prods. Liab. Litig., 852 F.3d 268 (3d. Cir. 2017).

In re Fosamax thus presented the Supreme Court with two important preemption issues: (1) who should decide the ultimate question, and (2) what does "clear evidence" of impossibility mean. With respect to the first issue, the Court in Merck could not have been more clear. Justice Breyer, writing for a majority of five, held "that a judge, not the jury, must decide the pre-emption question." Judges are in a better position than juries to assess the statutory and regulatory context for an agency's action and should, in theory, produce more uniform interpretations—"normally a virtue when a question requires a determination concerning the scope and effect of federal agency action." Merck, slip op. at 16.

With regard to the second issue, the Court was similarly unambiguous in one respect: "clear evidence" is not an evidentiary standard, but instead a matter of law in which "the judge must simply ask himself or herself whether the relevant federal and state laws irreconcilably conflict." Id. at 14 (quotation and alteration omitted). The Court also adopted a revised definition for the term:

"[C]lear evidence" is evidence that shows the court that the drug manufacturer fully informed the FDA of the justifications for the warning required by state law and that the FDA, in turn, informed the drug manufacturer that the FDA would not approve a change to the drug's label to include that warning.

Id. at 1-2. As to how a pharmaceutical defendant can show FDA disapproval, the Court noted that it must point to agency actions "taken pursuant to the FDA's congressionally delegated authority" and cited notice-and-comment rulemaking setting forth labeling standards, formal rejection of a warning label, or "other agency action carrying the force of law." Id. at 15. But the Court declined to apply the law to the facts in In re Fosamax, sending that task back to the Third Circuit.

Justice Thomas wrote separately to reiterate his distinct perspective on preemption, reasserting the skepticism he expressed in Wyeth that "physical impossibility" is the best proxy for determining preemption because "logical contradiction" could also have preemptive effects. Thomas, J., concurring, at 2. However, in this case, he would have gone further than the majority and found that Merck's preemption defense failed because it did not identify any law that would have prohibited it from adding a warning that would have satisfied state law. Id. at 4. In Justice Thomas' lone opinion, FDA's response letter rejecting Merck's proposed label change was of "tentative or interlocutory nature." Id. at 5. The letter "was not a final agency action with the force of law, so it cannot be 'Law' with pre-emptive effect." Id. But this position does not square with the majority opinion, which cited the statutory provision for response letters as an example of the agency formally rejecting a warning label. Slip op. at 15.

Justice Alito, joined by Chief Justice Roberts and Justice Kavanaugh, separately concurred and all but instructed the Third Circuit to find the claims against Merck preempted. While the majority gave passing attention to the statutory framework and regulatory history in the case, Justice Alito expounded further on both. As he noted, FDA was "for years . . . aware of this [atypical femoral fracture] issue, communicating with drug manufacturers, studying all relevant information, and instructing healthcare professionals and patients alike to continue to use Fosamax as directed." Alito, J., concurring, at 6. He stressed FDA's statutory duty to require label changes when the agency becomes aware that scientific evidence warrants a change, and noted that FDA requires Prior Approval Supplement applications when there are significant questions on drug labeling changes. Id. at 3-4. And he emphasized the Solicitor General's legal arguments on FDA's behalf—in particular, that the agency's decision not to require a change to the Fosamax label "reflected the FDA's determination that a new warning should not be included in the labeling of the drug." Id. at 6 (quotation and alterations omitted). Justice Alito clearly wanted to provide further guidance to the lower courts on how to interpret and apply the Court's decision, both on remand and in future cases. See id. at 1 (noting his concern that the majority opinion's discussion of the law and the facts may be misleading).

The Implications

The Court's decision in Merck that impossibility preemption is a question of law for the judge offers enormous strategic value to pharmaceutical defendants because it confirms that courts should conclusively rule on the defense, either on a motion to dismiss or on summary judgment. This also means that, in deciding such motions, judges will bring to bear their understanding of both the FDA regulatory scheme and preemption law generally.

With respect to the ultimate issue, the concurring opinions of Justice Thomas on one hand and Justice Alito, Chief Justice Roberts and Justice Kavanaugh on the other made fairly plain that they would reach divergent conclusions. But Justice Breyer's majority opinion leaves it for the Third Circuit to hash out on remand, using the newly articulated definition of "clear evidence." If, however, the Third Circuit heeds Justice Alito's direction to consider FDA's statutory duty to initiate label changes, as well as the totality of the regulatory history, a finding of preemption should result. The decision further reinforces the benefits of the Prior Approval Supplement process that Justice Alito cited as a means to engage with FDA on label changes.

An even more recent Supreme Court decision shows that the majority is inclined to let the lower courts continue to grapple with the preemption standard. In Dolin v. GlaxoSmithKline LLC, 901 F.3d 803 (2018), the Seventh Circuit found preemption of failure to warn claims based on correspondence from FDA rejecting a proposed label change. On May 28, 2019, just a week after deciding Merck, the Supreme Court denied certiorari, letting that preemption decision stand.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions